drugset / Trial / NCT02496897
Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir.
Timeline
- Start
- 2015-07
- Primary completion
- 2017-10-13
- Completion
- 2018-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FP-02.2 | Unknown | 150 ug | Intramuscular |
| Subject | FP-02.2 | Unknown | 500 ug | Intramuscular |
| Subject | IC31 | Other / unclassified | — | Intramuscular |